Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase 2 Trial of AEZS-108 in Chemotherapy Refractory Triple Negative, LHRH-positive Metastatic Breast Cancer.

NCT01698281 is registered in ClinicalTrials.gov with AEterna Zentaris as lead sponsor.

NCT NCT01698281
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01698281 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase 2 Trial of AEZS-108 in Chemotherapy Refractory Triple Negative, LHRH-positive Metastatic Breast Cancer.
Lead sponsor
AEterna Zentaris
Phase
Phase 2
Overall status
Terminated
Start date
December 31, 2012
Completion date
October 31, 2014
Enrollment
7 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer